Hamamatsu Photonics Expands Intended Use of NanoZoomer® MD Series in Europe to Include Cytology

Why It Matters

The approval broadens digital pathology’s reach, giving labs a single, validated tool for both tissue and cellular diagnostics and accelerating the shift toward fully digital, collaborative workflows.

Key Takeaways

• NanoZoomer MD now approved for Pap smears, liquid‑based cytology, FNAs
• Study validates digital cytology for primary diagnosis across specimen types
• Consolidates histology and cytology on a single digital platform
• Enhances remote case review and long‑term digital archiving
• Provides consistent color reproduction and automated focus for accurate analysis

Pulse Analysis

Digital pathology is moving from a niche capability to a core component of modern laboratory operations. Vendors have focused on high‑throughput whole‑slide imaging for histology, but cellular diagnostics have lagged due to the need for fine detail and color fidelity. Hamamatsu’s NanoZoomer MD series addresses this gap by extending its European intended use to cytology, allowing pathologists to digitize Pap smears, liquid‑based preparations, and fine‑needle aspirates with the same optical precision that has made its histology scanners popular.

The regulatory expansion is underpinned by a rigorous validation study published in Cytopathology, which demonstrated that digital images captured by the NanoZoomer MD meet diagnostic accuracy standards across a broad spectrum of specimen types. High‑resolution capture, automated focus, and stable scanning ensure that nuclear features and subtle chromatic nuances are preserved, a critical factor for cytology where diagnostic decisions hinge on minute morphological cues. Consistent color reproduction further reduces inter‑observer variability, supporting reproducible assessments in both routine and consultative settings.

For laboratories, the ability to run histology and cytology on a single platform simplifies workflow integration, reduces capital expenditures, and accelerates case turnaround. Remote review and collaborative diagnostics become more seamless, fostering telepathology networks that can serve regional or even national health systems. As hospitals and reference labs prioritize digital archiving for compliance and research, Hamamatsu’s move positions the NanoZoomer MD as a versatile cornerstone in the ongoing digital transformation of pathology.